OD-001's clean safety profile and efficacy comparable to or better than historic placebo benchmarks de-risk the program for Phase 2b/3. Key catalysts to watch: CTA filing for OD-002 (SLC15A4) in H2 2026, Phase 1/2a initiation for OD-002 in H1 2027, and OD-001 Phase 2b/2a topline data in H2 2027. The open-label design limits comparison to blinded trials, but biomarker and transcriptomic concordance strengthen the mechanistic case.
Price Chart
Executive Summary
Odyssey Therapeutics presented completed Phase 2a induction results for OD-001, a first-in-class oral RIPK2 scaffolding inhibitor, in moderate-to-severe ulcerative colitis at UEG Week 2026. The open-label trial met its primary endpoint (mean mMS reduction of 2.4 points, p<0.001) with a favorable safety profile (no SAEs, serious infections, or treatment-related discontinuations). The company is advancing OD-001 into Phase 2b monotherapy and Phase 2a combination trials with vedolizumab, with topline induction results expected in H2 2027.
Key Facts
- Phase 2a trial met primary endpoint: mean reduction in modified Mayo score of 2.4 points (p<0.001) at Week 12 across 56 evaluable patients
- Clinical remission at 20 mg BID was 27% (n=41) vs historic placebo benchmark of 10%; clinical response 61%; symptomatic remission 49%
- No serious adverse events, serious infections, treatment-related discontinuations, or liver function abnormalities during 12-week induction
- 20 mg BID selected as projected lowest maximally efficacious dose; comparable clinical remission in AT-naïve (29%) and AT-experienced (23%) patients
- Cash balance of $433M as of June 30, 2026, expected to fund operations into H2 2028
- Phase 2b monotherapy and Phase 2a combination (OD-001 + vedolizumab) trials planned with topline induction results expected H2 2027
Financial Impact
Positive catalyst for ODTX stock; OD-001 proof-of-concept strengthens pipeline value for a $100B+ I&I market opportunity; $433M cash runway into H2 2028
Risk Factors
- Open-label Phase 2a design without concurrent placebo control limits efficacy conclusions
- Phase 2b/3 trials may show lower efficacy in blinded, placebo-controlled settings
- Competitive landscape in IBD includes multiple advanced oral and biologic therapies (JAK inhibitors, IL-23, TL1A)
- Data remain subject to change until database lock
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-425684 |
| Document: odtx-20261020.htm | 0001193125-26-425684 |
| Document: odtx-ex99_1.htm | 0001193125-26-425684 |
| Document: 0001193125-26-425684-index-headers.html | 0001193125-26-425684 |
| Document: 0001193125-26-425684-index.html | 0001193125-26-425684 |
| Document: 0001193125-26-425684.txt | 0001193125-26-425684 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $18.99 $19.00 | ▲ +0.05% | ▼ −0.47% | $19.30 (+1.63%) |
Aug 4, 2026 11w ago | 8-K | $19.96 $20.89 | ▲ +4.66% | ▲ +4.86% | $19.30 (−3.31%) |
Jun 17, 2026 18w ago | 8-K | $19.07 $18.72 | ▼ −1.84% | ▼ −1.52% | $19.30 (+1.21%) |
May 11, 2026 24w ago | Insider Cluster | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.30 (+10.60%) |
May 8, 2026 24w ago | 424B4 | $17.45 $17.90 | ▲ +2.58% | ▲ +2.72% | $19.30 (+10.60%) |
May 8, 2026 24w ago | EFFECT | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
May 7, 2026 24w ago | 3 | $16.42 $17.45 | ▲ +6.27% | ▲ +6.04% | $19.30 (+17.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers